资源描述：
《替吉奥单药治疗晚期乳腺癌疗效及安全性观察.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、替吉奥单药治疗晚期乳腺癌疗效及安全性观察庞子娟北海市人民医院肿瘤科摘要：冃的观察替吉奥单药治疗晚期乳腺癌的疗效及安全性。方法82例晚期乳腺癌患者，采用数字表随机法分为观察组和对照组，各41例。观察组给予替吉奥单药治疗，对照组给予卡培他滨单药治疗，均于治疗2个周期后评价两组临床疗效，记录两组用药期间毒副反应。结果观察组缓解率(RR)为31.71%,对照组RR为34.15%,两组比较差异无统计学意义(P>0.05)。两组骨髓抑制、血小板减少、贫血、腹泻、口角炎、肝损害反应发生率及反应程度比较差异无统计学意义(
2、P>0.05)。观察组恶心呕吐I"发生率为26.83%,Ilf发生率为0,手足综合征I11发生率为4.88%,III"发生率为0;对照组恶心呕吐I11发生率为48.78%,III"发牛率为0,手足综合征I"发牛率为46.34%,11广发牛率为9.76%;观察组恶心呕吐、手足综合征发生率明显低于对照组，差异有统计学意义(P<0.05)。结论替吉奥疗效确切，服用方便、毒副反应易耐受，而且适合门诊治疗，因此初步认为替吉奥单药是晚期乳腺癌患者较合理的治疗方案，值得推广应用。关键词：晚期乳腺癌;替吉奥;卡培他滨;疗
3、效;安全性;收稿日期：2017-10-13ObservationonefficacyandsafetyoftegafurmonotherapyinthetreatmentofadvancedbreastcancerPANGZi-juanDepartmentofTumor,BeihaiPeople'sHospital:Abstract：ObjectiveToobservetheefficacyandsafetyoftegafurmonotherapyinthetreatmentofadvancedbreas
4、tcancer.MethodsAtotalof82advancedbreastcancerpatientsweredividedbyrandomnumbertablemethodintoobservationgroupandcontrolgroup,with41casesineachgroup.Theobservationgroupwastreatedwithtegafurmonotherapy,andthecontrolgroupwastreatedwithcapecitabinemonotherapy
5、.Aftertwocyclesoftreatment,theclinicalefficacyofthetwogroupswasevaluated,andthetoxicandsideeffectsbetweenthetwogroupswererecorded.ResultsTheobservationgrouphadremissionrate(RR)as31.71%,whichwas31.71%inthecontrolgroup,andtheirdifferencewasnotstatisticallys
6、ignificant(P>0.05)•Bothgroupshadnostatisticallysignificantdifferenceinbonemarrowsuppression,thrombocytopenia,anemia,diarrhea,angularcheilitis,liverdamagereactionrateandreactiondegree(P>0.05).TheobservationgrouphadincidenceofnauseaandvomitinginIJIdegreeas2
7、6.83%,III'IVdegreeas0,andincidenceofhandandfootsyndromeinI、IIdegreeas4.88%,IIIIVdegreeas0,whichwere48.78%,0,46.34%and9.76%inthecontrolgroup.Theobservationgrouphadobviouslylowerincidenceofnauseaandvomitingandhandandfootsyndromethanthecontrolgroup,andthedif
8、ferencewasstatisticallysignificant(P<0.05)•ConclusionTegafurshowsaffirmativeefficacy,andiseasytotake,anditssideeffectsiseasytotolerate.Itissuitableforoutpatienttreatment.Sotegafurmonotherapyismorereasonableforpatien
